Neuro-oncology
Clinical research in recurrent glioblastoma and diffuse gliomas at first relapse, with interest in treatment combinations for isocitrate dehydrogenase IDH wild-type disease and temozolomide-based regimens.
- Recurrent glioblastoma
- Diffuse gliomas
- IDH wild-type glioblastoma
- Temozolomide combinations
These studies reflect a focus on difficult-to-treat central nervous system tumors with recurrent disease.
Hematologic malignancies
Research in acute myeloid leukemia AML and chronic myelomonocytic leukemia CMML, especially in relapsed or refractory settings where standard treatment options are limited.
- Relapsed or refractory AML
- Relapsed or refractory CMML
- FLT3-ITD mutated AML
- Selected hematologic malignancies
The therapeutic emphasis includes targeted kinase inhibition in myeloid cancers.
Hepatobiliary oncology
Clinical interest in unresectable hepatocellular carcinoma HCC, particularly in patients previously treated with immune checkpoint inhibitors and with limited surgical options.
- Unresectable HCC
- Previously treated hepatocellular carcinoma
- Immune checkpoint inhibitor combinations
- Decitabine priming strategies
The work centers on advanced liver cancer populations requiring additional systemic treatment options.
Targeted and immuno-oncology therapies
Development activity spans FLT3, KIT, and CSF1R inhibition, together with combinations involving atezolizumab and epigenetic modulation with decitabine.
- FLT3, KIT and CSF1R inhibition
- Atezolizumab combinations
- Decitabine priming
- Antitumor activity in resistant disease
These programs cover both targeted therapy and immunotherapy approaches across solid tumors and blood cancers.
